| Name | Title | Contact Details |
|---|
Groups360™️ was founded in 2014 with the goal of simplifying and transforming the ways meetings are booked. The company`s search engine, GroupSync™️, using its proprietary matching algorithms designed specifically for meeting planners, has helped place thousands of events at the right venue, saving planners time and money. GroupSync`s price predictor tool delivers improved transparency, reducing time and effort required to book meetings for both the hotel and the planner. Groups360`s management team has decades of experience in the meetings and events industry and provides the right mix of technology and experienced advisors. Using GroupSync, planners can search more than 200,000 properties in 225 countries and territories.
Krames Corporate is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
O. I. Medical is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Connections Health Solutions, LLC is the pioneer of behavioral health crisis care. The Company operates the two largest behavioral health crisis facilities in the nation and provides a range of services to help stabilize and treat people with mental health and substance use diagnoses. Connections` model emphasizes providing treatment in the least restrictive setting and has demonstrated improved quality and cost savings, including significantly reducing hospital admissions in Medicaid and behavioral health populations. For more information and crisis resources, please visit www.connectionshs.com. We believe that people do best when they don`t have to wait a long time to get what they need. As a result, we have created a culture in which we welcome everyone regardless of clinical complexity, provide intervention as quickly as possible, and partner with community support systems to maximize recovery. Our corporate mission is simple: to address any behavioral health need, at any time.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.